SJ
Samie Jaffrey, M.D., Ph.D.
Scientific Advisor, Greenburg-Starr Professor at Weill Cornell Medicine
Chimerna TherapeuticsChimerna Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Tornado Platform - RNA Aptamers | Alzheimer's Disease, Parkinson's Disease, ALS (Lou Gehrig's Disease), Non-alcoholic steatohepatitis (NASH) | Pre-clinical |
| Tornado-based microRNA Sponge Libraries | MicroRNA-related diseases (e.g., Cancer, Heart Disease, Autoimmune, Neurodevelopmental) | Platform/Tool Development |
| Target RNA‐directed miRNA Degradation (TDMD) Platform | MicroRNA-related diseases (Target Discovery) | Platform/Tool Development |
| Recombinant Protein Yield Enhancement Technology | Biomanufacturing / Production of biologic drugs | Platform/Tool Development |
Leadership Team at Chimerna Therapeutics
BP
Brian Pickering, Ph.D.
Chief Executive Officer
JL
Jacob Litke, Ph.D.
Chief Scientific Officer, President